Key facts
- This page summarizes Briggs Morrison's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Aug 2023, 06:50.
Briggs Morrison - 09 Aug 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)
- Reporting relationship
- Director
- Issuer ticker
- SNDX
- Reported as of
- 09 Aug 2023
- Net transaction value
- -$501,864
- SEC form
- 4
- Accepted by SEC
- 10 Aug 2023, 06:50:32 UTC
- Prior SEC filing
- 11 Jul 2023
- Next SEC filing
- 09 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael A. Metzger, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Briggs Morrison filed Form 4 for Syndax Pharmaceuticals Inc (SNDX) on 10 Aug 2023.
Change
- Previous filing in this sequence was filed on 11 Jul 2023.
- Current net transaction value: -$501,864.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SNDX
transaction
Common Stock
Options Exercise
- Transaction value
- $463,538
- Shares
- +52,855
- Change %
- +296%
- Price
- $8.77
- Shares after
- 70,691
- Date
- 09 Aug 2023
- Ownership
- Direct
SNDX
transaction
Common Stock
Sale
- Transaction value
- $965,402
- Shares
- -52,855
- Change %
- -75%
- Price
- $18.27
- Shares after
- 17,836
- Date
- 09 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SNDX
transaction
Derivative
Stock Options (Right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -52,855
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,855
- Exercise price
- $8.77
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
Following the sales reported in this Form 4, the Reporting Person has a total of 559,142 options to purchase shares of common stock that are vested and immediately exercisable and a total of 247,875 options to purchase shares of common stock that have not yet vested.
Footnote F2
The sale prices ranged from $18.02 to $18.41.
Footnote F3
This option is fully vested.